Standard Biotools (LAB) EBITDA (2010 - 2026)

Standard Biotools (LAB) has reported EBITDA for 17 consecutive years, with -$25.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 1.2% year-over-year to -$25.4 million in Q2 2026; TTM through Jun 2026 was -$95.5 million, a 9.47% increase from a year earlier, with the FY2025 full-year figure at -$110.2 million, up 13.52% from the prior year.
• EBITDA was -$25.4 million for Q2 2026 at Standard Biotools, down from -$12.5 million in the prior quarter.
• Over five years, EBITDA peaked at -$12.5 million in Q1 2026 and troughed at -$60.2 million in Q1 2024.
• A 5-year average of -$26.9 million and a median of -$25.9 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA tumbled 262.7% in 2024 and jumped 55.19% in 2025, its largest moves.
• Over 5 years, EBITDA stood at -$21.1 million in 2022, then retreated by 1.3% to -$21.4 million in 2023, then decreased by 21.96% to -$26.1 million in 2024, then rose by 5.51% to -$24.6 million in 2025, then decreased by 3.02% to -$25.4 million in 2026.
• The last three EBITDA figures came in at -$25.4 million (Q2 2026), -$12.5 million (Q1 2026), and -$24.6 million (Q4 2025), per Business Quant data.